Bearish flow noted in Merck (MRK) with 11,740 puts trading, or 3x expected. Most active are Feb-25 95 puts and Jan-25 100 calls, with total ...

Bernstein analyst Courtney Breen maintained a Hold rating on Merck & Company (MRK – Research Report) yesterday and set a price target of $110.00. The company’s shares closed last Friday at $99.70.

Shares of Merck & Co. Inc. MRK slipped 0.03% to $99.14 Friday, on what proved to be an all-around great trading session for ...

Shares of Merck & Co. Inc. MRK slumped 0.31% to $99.17 Thursday, on what proved to be an all-around dismal trading session ...

Dec 18 (Reuters) - Merck (MRK.N), opens new tab has signed a licensing deal worth up to $2 billion for Chinese biotech Hansoh Pharma's (3692.HK), opens new tab experimental oral drug to treat ...

Dec 31 (Reuters) - UK's Medicines and Healthcare products Regulatory Agency said on Tuesday it had approved Merck's (MRK.N), opens new tab therapy to treat a rare lung condition, marking another ...

MHRA approves Merck's Winrevair (sotatercept) for adults with PAH to enhance exercise capacity and reduce functional limitations. A 24-week study showed sotatercept improved 6-minute walking ...

Merck's strong financial performance in oncology and vaccines drove a 9% sales increase earlier in Q1 of 2024, despite challenges with other products. Promising future developments include ...

Merck and Chinese biopharmaceutical company Hansoh Pharma enter into an exclusive global license agreement for HS-10535. HS-10535 is an investigational preclinical oral small molecule GLP-1 ...

Merck & Co. has added a second GLP-1 candidate to its pipeline, paying China’s Hansoh Pharma $112 million upfront for a preclinical drug. The Big Pharma already has efinopegdutide, a dual GLP-1 ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Hansoh Pharma, a Chinese biopharmaceutical company, today announced that they have ...